How to win the next Silicon Valley tech race
Citrix, a Palo Alto-based provider of cloud computing services, reported better-than-expected earnings Thursday.
The company also reported a 3% jump in revenue, with sales rising to $839 million from $739 million.
But it also reported an increase in expenses, including its share of net loss of $1.6 billion.
The net loss widened to $1 billion from $1,081 million, and Citrix shares fell as much as 5% in after-hours trading.
Citrix chief executive John Quigley said in a statement that the company has taken a “significant amount of pressure off” in the second half.
He added that the “growth has accelerated” and that Citrix expects to report $837 million in net income in its fiscal fourth quarter, compared with $823 million last year.
Citix was one of several companies that benefited from surging sales of new products such as the telenasome drug tetraphase, which is also used to treat rare cancers.
Citigroup Inc. has been working on a drug for this disease, which affects around one-quarter of all Americans, according to the company.
Citis drug sales rose in the quarter.
On Thursday, Citix reported a $1 million increase in quarterly net income.
CitiX reported a 0.4% gain, but it said it would post a $8.1 billion loss in its second-quarter.
The Nasdaq composite index fell 0.3% to 16,038.49.
Microsoft Corp. and Cisco Systems Corp. each reported quarterly earnings.
Microsoft said it had a quarterly profit of $3.1 million for the third quarter.
Cisco said it earned $1 for every $1 it spent on research and development, up from $8 a year ago.
Cisco also said it expected its fourth-quarter revenue to be higher than analysts expected, citing new cloud-based products, new cloud services and software-as-a-service services.
The stock was down 1.4%, or $9.60, at $30.77.